Nuclear autoantigen CENP-B transactivation of the epidermal growth factor receptor via chemokine receptor 3 in vascular smooth muscle cells

Arthritis and Rheumatism

Volumn 60, Issue 9, 2009, Pages 2805-2816

  Robitaille, Geneviève ^a   Christin, Marie Soleil ^a   Clément, Isabelle ^a   Senécal, Jean Luc ^a   Raymond, Yves ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CENTROMERE PROTEIN B; CHEMOKINE RECEPTOR CCR3; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MESSENGER RNA; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; DESENSITIZATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRANSACTIVATION; VASCULAR SMOOTH MUSCLE;

AUTOANTIBODIES; CELLS, CULTURED; CENTROMERE PROTEIN B; HUMANS; INTERLEUKIN-8; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUSCLE, SMOOTH, VASCULAR; PULMONARY ARTERY; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CCR3; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 69449091700     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24765     Document Type: Article

References (42)

1. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007;25:787-820.
2. Hayes IM, Jordan NJ, Towers S, Smith G, Paterson JR, Earnshaw JJ, et al. Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb Vasc Biol 1998;18:397-403. (Pubitemid 28125634)
3. Schecter AD, Calderon TM, Berman AB, McManus CM, Fallon JT, Rossikhina M, et al. Human vascular smooth muscle cells possess functional CCR5. J Biol Chem 2000;275:5466-5471 (Pubitemid 30115180)
4. Howard OZ. Autoantigen signalling through chemokine receptors. Curr Opin Rheumatol 2006;18:642-646
5. Oppenheim JJ, Dong HF, Plotz P, Caspi RR, Dykstra M, Pierce S, et al. Autoantigens act as tissue-specific chemoattractants. J Leukoc Biol 2005;77:854-861
6. Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002;196:781-791
7. Howard OM, Dong HF, Su SB, Caspi RR, Chen X, Plotz P, et al. Autoantigens signal through chemokine receptors: uveitis antigens induce CXCR3- and CXCR5-expressing lymphocytes and immature dendritic cells to migrate. Blood 2005;105:4207-4214 (Pubitemid 40720764)
8. Robitaille G, Henault J, Christin MS, Senecal JL, Raymond Y. The nuclear autoantigen CENP-B displays cytokine-like activities toward vascular smooth muscle cells. Arthritis Rheum 2007;56:3814-3826 (Pubitemid 350100714)
9. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996;379:557-560 (Pubitemid 26049585)
10. Adachi T, Cui CH, Kanda A, Kayaba H, Ohta K, Chihara J. Activation of epidermal growth factor receptor via CCR3 in bronchial epithelial cells. Biochem Biophys Res Commun 2004;320:292-296 (Pubitemid 38798864)
11. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells: metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 2001;276:7957-7962 (Pubitemid 37385594)
12. Yang X, Zhu MJ, Sreejayan N, Ren J, Du M. Angiotensin II promotes smooth muscle cell proliferation and migration through release of heparin-binding epidermal growth factor and activation of EGF-receptor pathway. Mol Cells 2005;20:263-270
13. Zwick E, Hackel PO, Prenzel N, Ullrich A. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci 1999;20:408-412 (Pubitemid 29450362)
14. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999;402:884-888 (Pubitemid 30017171)
15. Henault J, Robitaille G, Senecal JL, Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 2006;54:963-973
16. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002;81:154-167 (Pubitemid 34218570)
17. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-590
18. Fields TA, Casey PJ. Signalling functions and biochemical properties of pertussis toxin-resistant G-proteins. Biochem J 1997;321:561-571
19. Kodali RB, Kim WJ, Galaria II, Miller C, Schecter AD, Lira SA, et al. CCL11 (eotaxin) induces CCR3-dependent smooth muscle cell migration. Arterioscler Thromb Vasc Biol 2004;24:1211-1216 (Pubitemid 38880010)
20. Neel NF, Schutyser E, Sai J, Fan GH, Richmond A. Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev 2005;16:637-658 (Pubitemid 41505521)
21. Zimmermann N, Conkright JJ, Rothenberg ME. CC chemokine receptor-3 undergoes prolonged ligand-induced internalization. J Biol Chem 1999;274:12611-12618 (Pubitemid 129518029)
22. Sabroe I, Jorritsma A, Stubbs VE, Xanthou G, Jopling LA, Ponath PD, et al. The carboxyl terminus of the chemokine receptor CCR3 contains distinct domains which regulate chemotactic signaling and receptor down-regulation in a ligand-dependent manner. Eur J Immunol 2005;35:1301-1310 (Pubitemid 40542238)
23. Hertel C, Coulter SJ, Perkins JP. A comparison of catecholamine-induced internalization of β-adrenergic receptors and receptor-mediated endocytosis of epidermal growth factor in human astrocytoma cells: inhibition by phenylarsine oxide. J Biol Chem 1985;260:12547-12553 (Pubitemid 16233457)
24. Proudfoot AE, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996;271:2599-2603 (Pubitemid 26047869)
25. Elsner J, Petering H, Hochstetter R, Kimmig D, Wells TN, Kapp A, et al. The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3. Eur J Immunol 1997;27:2892-2898 (Pubitemid 27478359)
26. Luttrell LM, Daaka Y, Lefkowitz RJ. Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr Opin Cell Biol 1999;11:177-183 (Pubitemid 29164031)
27. Heath H, Qin S, Rao P, Wu L, LaRosa G, Kassam N, et al. Chemokine receptor usage by human eosinophils: the importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997;99:178-184 (Pubitemid 27053460)
28. Uguccioni M, Mackay CR, Ochensberger B, Loetscher P, Rhis S, LaRosa GJ, et al. High expression of the chemokine receptor CCR3 in human blood basophils: role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest 1997;100:1137-1143 (Pubitemid 27386297)
29. Beaulieu S, Robbiani DF, Du X, Rodrigues E, Ignatius R, Wei Y, et al. Expression of a functional eotaxin (CC chemokine ligand 11) receptor CCR3 by human dendritic cells. J Immunol 2002;169:2925-2936 (Pubitemid 35013134)
30. Franz-Bacon K, Dairaghi DJ, Boehme SA, Sullivan SK, Schall TJ, Conlon PJ, et al. Human thymocytes express CCR-3 and are activated by eotaxin. Blood 1999;93:3233-3240 (Pubitemid 29220889)
31. Stellato C, Brummet ME, Plitt JR, Shahabuddin S, Baroody FM, Liu MC, et al. Expression of the C-C chemokine receptor CCR3 in human airway epithelial cells. J Immunol 2001;166:1457-1461 (Pubitemid 32114623)
32. Wakugawa M, Nakamura K, Akatsuka M, Kim SS, Yamada Y, Kawasaki H, et al. Expression of CC chemokine receptor 3 on human keratinocytes in vivo and in vitro - upregulation by RANTES. J Dermatol Sci 2001;25:229-235 (Pubitemid 32184511)
33. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002;45:173-202. (Pubitemid 36139815)
34. Stenmark KR, Mecham RP. Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol 1997;59:89-144. (Pubitemid 27142436)
35. 2B-adrenergic receptor activates MAPK via a pathway involving arachidonic acid metabolism, matrix metalloproteinases, and epidermal growth factor receptor transactivation. J Biol Chem 2002;277:19882-19888
36. Mulligan-Kehoe MJ, Simons M. Current concepts in normal and defective angiogenesis: implications for systemic sclerosis. Curr Rheumatol Rep 2007;9:173-179 (Pubitemid 46932725)
37. Salerni R, Rodnan GP, Leon DF, Shaver JA. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977;86:394-399 (Pubitemid 8078946)
38. Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003;48:203-209 (Pubitemid 36091664)
39. Steen VD. Epidemiology and classification of scleroderma. In: Hochberg MA, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 4th ed. Philadelphia: Mosby Elsevier; 2008. p. 1361-1367
40. Harris ML, Rosen A. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 2003;15:778-784 (Pubitemid 38156307)
41. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42.
42. Boin F, Rosen A. Autoimmunity in systemic sclerosis: current concepts. Curr Rheumatol Rep 2007;9:165-172 (Pubitemid 46932724)